Abstracts measurement experts to generate items, responses, and instructions for the new scale. Cognitive interviews were conducted with an additional 15 idiopathic RLS patients (aged 25-68) to ensure understanding of the new measure, concept comprehensiveness, and to identify any necessary revisions to the items and conceptual framework. RESULTS: Twenty-three items were generated from patient quotes obtained during the concept elicitation interviews. Impacts on next day functioning spontaneously attributed to disturbed sleep due to RLS symptoms included: activities of daily living (i.e., work, household chores), cognitive functioning (i.e., concentration, forgetfulness, mental tiredness, alertness), emotional functioning (i.e., irritability, depressed mood), physical functioning (i.e., physical tiredness, active leisure activities), energy, daytime sleepiness, and social functioning (i.e., relationships, social activities/situations). Concept saturation was achieved. Modifications to questions and responses were based on feedback provided during cognitive interviews. The final measure consists of 14 items assessed "today" and rated on a severity numeric rating scale. CONCLU-SIONS: The RLS-NDI is an evaluative tool with demonstrated content validity to assess the impact of disturbed sleep due to RLS symptoms on RLS patients' next day functioning. is a daily diary designed to measure motor impairment in PD patients with fluctuating symptoms. Consistent with the FDA's final guidance on patient-reported outcome measures, this study aimed to evaluate the content validity of the SCOPA-DC in the US and determine the feasibility of adding items that measure non-motor symptoms using qualitative techniques. METHODS: A literature review identified the most dominant non-motor symptoms experienced by PD patients with fluctuating symptoms. Three focus groups were conducted with PD patients (n = 24) to identify themes that specifically addressed the study objectives. The original SCOPA-DC was modified based on findings from the literature review and patient input. A fourth focus group (n = 9) consisted of a cognitive debriefing of the revised SCOPA-DC that included additional items and modified structure based upon the previous results. RESULTS: Findings from the focus groups demonstrated support for the content of the original SCOPA-DC, generally finding it to be clear and intuitive, despite difficulties with some item definitions, time frames, and response labels. With respect to non-motor symptoms, seven domains were consistently mentioned: fatigue, concentration/memory, anxiety, pain, difficulty swallowing, frequent urination, and sweating. The cognitive debriefing focus group reported that the revised SCOPA-DC format was easier to use, provided better focus on the items and time frames, and more adequately captured experiences throughout the day as compared to the original. CONCLUSIONS: Non-motor symptoms occur frequently in PD patients with fluctuating symptoms and have a significant impact on health-related quality of life. A reliable and validated patient-reported daily diary may improve the ability to describe PD progression by accurately measuring both motor and non-motor symptoms. Additional quantitative research is needed to evaluate the psychometric properties of the revised SCOPA-DC.
PHQ-4 (r = −0.28 to −0.47), MIDAS (r = −0.42 to −0.58), and HIT-6 (r = −0.55 to −0.71). Known groups validity indicated significant differences (p < 0.0001) in the hypothesized direction between CM, HEM, and LEM for RP (F = 58.74), RR (F = 91.78), and EF (F = 153.38). CONCLUSIONS: The MSQ is a reliable and valid questionnaire that can differentiate the functional impact between CM, HEM, and LEM.
PND27 CONFIRMATORY FACTOR ANALYSIS AND DIFFERENTIAL ITEM FUNCTIONING ANALYSIS OF THE MIGRAINE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE VERSION 2.1 IN CHRONIC MIGRAINEURS
Rendas-Baum R 1 , Maglinte GA 2 , DeRosa M 1 , Yang M 1 , Varon SF 2 1 QualityMetric Incorporated, Lincoln, RI, USA, 2 Allergan, Inc, Irvine, CA, USA OBJECTIVES: The Migraine-Specific Quality of Life Questionnaire Version 2.1 (MSQ) is a 14-item health-related quality of life instrument that measures the functional impact of migraine across three domains: Role Function-Preventive (RP), Role Function-Restrictive (RR), and Emotional Function (EF). This study evaluated the factor structure and cross-cultural comparability of the MSQ in Chronic Migraine (CM) sufferers. METHODS: Cross-sectional data were collected via web-based survey, across eight countries. Respondents were classified as having CM per ICHD-2 criteria with ≥15 headache days/month (n = 499). Confirmatory factor analysis (CFA) of the 3-factor model was conducted using the robust maximum likelihood estimator (MLR) assuming multivariate normality. Goodness-of-fit was assessed by the comparative fit index (CFI), Tucker-Lewis Index (TFI), and root mean square error of approximation (RSMEA). Differential item functioning (DIF) was tested using ordinal logistic regression of MSQ item scores on group membership and trait level explanatory variables. Groups were based on country (Australia, Canada, Germany, Spain, France, Great Britain, Italy, United States) and language (English/non-English). Nonuniform DIF (significant interaction term between group membership and trait level, p < 0.05) and uniform DIF (>10% change in the trait level coefficient resulting from removal of the group membership term from the model) were identified.
RESULTS:
The 3-factor model demonstrated good fit (CFI = 0.97; TFI = 0.96; RMSEA = 0.07) among CM sufferers. Factor loadings ranged between 0.72 and 0.89, and had similar values across the three factors. Most MSQ items showed absence of DIF. Non-uniform country DIF was identified in items 5 (inability to concentrate; p = 0.028) and 12 (fed up or frustrated; p = 0.037). Item 12 also presented non-uniform DIF related to language (p = 0.010). CONCLUSIONS: Among Chronic Migraineurs, the MSQ provides a valid measure of RP, RR, and EF, yielding domain scores that can be reliably compared across languages and countries. multiple sclerosis heading term or by using quality of life and multiple sclerosis as separate MeSH terms. Urinary bladder was entered as a heading term, and all associated subheadings were included in the search box. Studies were included if a HRQOL instrument measuring bladder function or urinary incontinence was administered to a sample of MS patients. References in these articles were searched for additional studies that met inclusion criteria. RESULTS: Six articles initially met inclusion criteria. An additional 2 articles were found from their references. A total of 8 different instruments were used ranging from 6 to 30 items and tested across 3 to 10 different domains. Articles varied in terms of sample size (30 to 9,688 participants), study design (cross-sectional vs. prospective cohort), and objectives (HRQOL impact vs. instrument validation). Six disease-specific HRQOL instruments were originally designed for use in other populations, and 3 were gender specific. Moderate to severe bladder dysfunction in patients with MS was prevalent in 49% to 79% of the study samples and the urinary symptoms negatively impacted HRQOL in all the studies. CONCLUSIONS: The use of HRQOL instruments specific to bladder dysfunction in patients with MS is limited. Study design variability made it difficult to assess overall impact of bladder symptoms on HRQOL. Further validation of existing instruments that include both sexes and whose bladder dysfunction is of neurogenic origin is needed.
PND30 NATALIZUMAB TREATMENT IS ASSOCIATED WITH AN IMPROVEMENT IN PATIENT-REPORTED FATIGUE AND COGNITIVE FUNCTION OVER TIME
Stephenson JJ 1 , Hou L 1 , Agarwal SS 2 , Rajagopalan K 2 , Kamat SA 1 1 HealthCore, Inc., Wilmington, DE, USA, 2 Biogen Idec, Wellesley, MA, USA OBJECTIVES: To evaluate changes in patient-reported fatigue and cognitive function after one year of natalizumab treatment in MS patients. METHODS: The study population consists of MS patients initiating natalizumab treatment who agreed to participate in a 12-month longitudinal study. The study assessed patient experiences with natalizumab using validated patient-reported outcome (PRO) measures prior to treatment initiation and after 3 rd , 6 th and 12 th infusions. The current analysis reports change in fatigue and cognitive functioning from baseline through the 12 th natalizumab infusion. Fatigue is measured by the 5-question Modified Fatigue Impact Scale-5 (MFIS-5, score range 0-20) with lower scores indicating lower impact of fatigue on physical, cognitive, and psychosocial functioning; cognitive function is measured by the 6-question Medical Outcomes Study Cognitive Functioning Scale (MOS-Cog Scale, score range 6-36) with higher scores indicating better reasoning skills, memory, concentration, ability to start several actions at one time and ability to react to what is said or done. Regression analysis was used to control for baseline (BL) covariates such as age, years since MS diagnosis, number of natalizumab infusions received, MS level of disability and functional status, number of MS drugs used prior to natalizumab and comorbidity burden. RESULTS: Results from this on-going study are presented for 192 patients completing the BL through 12 th infusion follow-up surveys. The mean number of years since MS diagnosis was 10.16 (SD = 8.23). Most patients were female (78%) and the mean age was 46.09 (SD = 10.78). On average, MFIS scores decreased significantly (BL 12.23 ± 2.2; 12 th infusion score 10.97 ± 2.2, p < 0.001) and MOS-Cog scores increased significantly over time (BL 25.8 ± 1.4; 12 th infusion score 26.91 ± 1.4, p < 0.001) after controlling for covariates. CONCLUSIONS: MS patients reported improvements in the impact of fatigue and overall cognitive function after one year of natalizumab treatment.
PND31 IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS RECEIVING NATALIZUMAB IN THE UNITED STATES
Hou L 1 , Stephenson JJ 1 , Agarwal SS 2 , Rajagopalan K 2 , Kamat SA 1 1 HealthCore, Inc., Wilmington, DE, USA, 2 Biogen Idec, Wellesley, MA, USA OBJECTIVES: To assess the change in general health-related quality of life (HRQoL) of multiple sclerosis (MS) patients after one year of natalizumab treatment. METHODS: MS patients, newly starting natalizumab, were recruited to participate in a longitudinal observational study to assess general health-related quality of life using the SF-12v2 prior to natalizumab initiation and after the 3 rd , 6 th and 12 th infusions. Higher physical component summary scores (PCS) and mental component summary scores (MCS) on the SF-12v2 indicate better HRQoL. Statistical regression models were used to evaluate changes in PCS and MCS scores from baseline through the 12 th infusion after controlling for baseline patient-level and treatment characteristics. RESULTS: Data for 192 patients who had completed the baseline through 12 th infusion assessments of this ongoing study are reported. The mean age was 46.09 (SD = 10.78) and the majority of patients were female (78%). The mean number of years since MS diagnosis was 10.16 (SD = 8.23). The PCS score improved significantly from baseline (BL 33.30 ± 7.12, 12 th infusion 35.91 ± 7.12; p < 0.001); similar improvements were observed in the MCS scores which also improved significantly from baseline (BL 43.12 ± 1.53, 12 th infusion 47.95 ± 1.53; p < 0.001). CONCLUSIONS: Patients reported improvements in general HRQoL measures after one year of natalizumab treatment in the usual care setting. These results are consistent with results from pivotal clinical trials and document the beneficial impact of natalizumab on HRQoL of MS patients. To assess duloxetine utilization among commercially-insured fibromyalgia patients. METHODS: This study analyzed administrative claims for fibromyalgia patients aged 18-64 who initiated duloxetine in 2006. Initiation was defined as no duloxetine coverage in the prior 90 days, with the first duloxetine prescription dispense date as the "index date." Patients were excluded if they had less than 30 duloxetine supply days in the 12-month post-index period, or diagnosis of diabetic peripheral neuropathic pain or depression in the 12 months pre-index period. All duloxetine patients were classified in five cohorts based on index dosage: <30 mg, 30 mg, 31-59 mg, 60 mg, and >60 mg. Changes in dosage, average daily dosage (ADD), and adherence to duloxetine (medication possession ratio ≥0.8 as high adherence) were compared across cohorts. Multivariate regression models were performed to examine the association between index dosage and health care costs, controlling for demographics and clinical characteristics. RESULTS: Of 4,869 fibromyalgia patients identified, 4.4% had an index dosage of <30 mg, 22.4% of 30 mg, 5.9% of 31-59 mg, 60.4% of 60 mg, and 7.0% of >60 mg. 28% of total patients experienced any increase in dosage, while 15.9% experienced any decrease. Among those with any dosage change (n = 1,651), patients with an index dosage of 31-59 mg had the shortest duration before any dosage change (89 days), followed by those in the <30 mg, >60 mg, 30 mg, and 60 mg (95, 100, 104, and 139 days, respectively) cohorts. ADD increased with index dosage. Patients with <60 mg index dosage were less likely to be adherent than those in the 60 mg cohort (odds ratios ranged 0.61 to 0.78, all p < 0.05). Patients in the >60 mg cohort had higher total health care costs compared with those in the 60 mg cohort (adjusted difference: $3,747, p < 0.05). CONCLUSIONS: About one-third of duloxetine treated fibromyalgia patients experienced any dosage change. Duloxetine adherence and ADD, and health care costs differ by duloxetine index dosage.
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PND33 PREDICTORS OF PAIN MEDICATION SELECTION AMONG PATIENTS DIAGNOSED WITH FIBROMYALGIA
Zhao Y 1 , Chen SY 2 , Boulanger L 2 , Nagar S 2 , Fraser K 2 , Wu N 2 1 Eli Lilly and Company, Indianapolis, IN, USA, 2 Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA OBJECTIVES: Multiple pharmacologic therapies have been recommended for managing fibromyalgia. However, the factors associated with each treatment initiation have not been well established. This study assessed demographic and clinical predictors of duloxetine versus other pain medications dispensed among patients with fibromyalgia. METHODS: Employing a retrospective cohort design and data from commercial insurance, this study examined predictors of treatment among fibromyalgia patients who were 18 to 64 years old and initiated duloxetine versus selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), venlafaxine, gabapentin, pregabalin, tramadol or non-tramadol narcotics between January 1, 2007 and December 31, 2008. Treatment initiation was defined as no access to the same medication over the previous 90 days, and the most recent initiation date was set as the index date. All patients selected had at least 1 fibromyalgia diagnosis (ICD-9-CM: 729.1) in the 12 months prior to initiation of each study therapy. Multiple logistic regression models were estimated to assess predictors of initiating duloxetine versus each of the other fibromyalgia therapies. RESULTS: Commercially insured fibromyalgia patients (n = 117,305) were on average 48 years of age, and 76% were females. Common fibromyalgia-related comorbidities were low back pain (35%), osteoarthritis (17%), and diabetes (12%). After controlling for demographic and clinical characteristics, those 35+ years of age, females, and patients who received SSRIs, TCAs, venlafaxine, gabapentin, or pregabalin over the 1-year pre-index period were generally more likely to initiate duloxetine than the other study medications. Other predictors of duloxetine initiation included higher prescription copayment and history of rheumatoid arthritis, osteoporosis, and sleep disturbance. CONCLUSIONS: These findings indicate that age, cost sharing, presence of selected comorbidities, and prior use of certain medications to treat pain were significant predictors of duloxetine initiation among working age, commercially insured fibromyalgia patients.
